Introduction
============

Lung cancer is a significant global health problem, with an estimated total of 228,150 new cases and 142,670 deaths in the United States in 2019 ([@b1-ol-0-0-11112]). Lung cancer is the leading cause of cancer-related death worldwide ([@b2-ol-0-0-11112]). Non-small cell lung cancer (NSCLC) and small cell lung cancer are the two major histological categories of lung cancer. Patients with NSCLC occasionally present with malignant pleural effusion (MPE) or pericardial effusion (MPCE) at the initial diagnosis ([@b3-ol-0-0-11112]) and these patients are classified as being in the M1 stage according to the 7th edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system ([@b4-ol-0-0-11112]). The median survival time of these patients with the same stage can differ from 3 months to 1 year ([@b5-ol-0-0-11112]). Determining the accurate outcome for specific patients remains a challenge.

There are several published studies on the survival prediction of patients with MPE and MPCE ([@b6-ol-0-0-11112]--[@b8-ol-0-0-11112]), most of which are dependent on biomarker concentrations in the effusions. However, to the best of our knowledge, a survival model specifically describing the prognosis of patients with MPE or MPCE with different demographic and clinicopathological characteristics is not available. Predicted survival information from a nomogram may assist patients and physicians in making appropriate decisions with regards to management.

The aim of the present study was to construct a survival model capable of predicting prognosis of patients with stage IV NSCLC with MPE or MPCE at initial diagnosis, using the data in the Surveillance, Epidemiology, and End Results (SEER) database and to establish a nomogram to illustrate the association between the prognostic factors and overall survival (OS).

Patients and methods
====================

### Study population

The present study was approved by The Ethics Committee of Fuyang People\'s Hospital. Permission was obtained from the Surveillance, Epidemiology and End Results (SEER) Program to access the SEER research data files (reference no. 16924-Nov2017). Informed consent was obtained from each patient in the validation dataset. However, consent in the SEER training cohort was waived considering the anonymous, observational, registry-based and publicly available nature of the data. Patient data on individuals was not reported.

The patient cohort data for the training dataset were obtained from the SEER Program ([seer.cancer.gov](seer.cancer.gov)) SEER\*Stat Database. Initial patient selection was performed by specifying the site recode as 'Lung and Bronchus'. Patients with MPE or MPCE at initial diagnosis who were diagnosed between January 2010 and December 2015 were included for further study by selecting 'CS Mets at DX' with codes 15--18, 20--21, 32, 42 and 52. The codes were defined as follows: 15, malignant pleural effusion, ipsilateral or same lung; 16, malignant pleural effusion, contralateral or other lung; 17, malignant pleural effusion, ipsilateral and contralateral lungs; 18, malignant pleural effusion, unknown if ipsilateral or contralateral lung; 20, malignant pericardial effusion; 21, malignant pericardial effusion plus contralateral or bilateral pleural effusion; 32, distant lymph nodes plus pleural or pericardial effusion; 42, distant metastasis plus extension to contralateral lung; and 52, distant metastasis plus distant lymph nodes plus pleural or pericardial effusion. The exclusion criteria were as follows: i) Status of MPE or MPCE was unknown at initial diagnosis; ii) missing or incomplete information regarding race, stage, grade, histology, primary site or laterality; and iii) death certificate only or autopsy only cases in the SEER database. A total of 10,268 patients from the SEER database were included, comprising 5,827 (56.7%) men and 4441 (43.3%) women. The median age at diagnosis in the training dataset was 70 years (age range, 21--86 years).

The independent external validation dataset consisted of patients with NSCLC with MPE or MPCE at initial diagnosis between January 2013 and January 2018 who were hospitalized at three institutions in China (Fuyang People\'s Hospital, Fuyang Second People\'s Hospital and Affiliated Fuyang Hospital of Anhui Medical University; all Fuyang, China). Patient data, including survival time, age, race, sex, grade, histology, laterality, stage, physical status, LDH levels in effusion, neutrophil-to-lymphocyte ratio and status of MPE or MPCE at initial diagnosis, were collected to validate the nomogram and to compare with previous predictive model ([@b7-ol-0-0-11112]). Patients were followed-up every 2 weeks and the observations for this dataset were censored on January 1st, 2019. Patients with missing values for the above variables were excluded. In the validation dataset, 169 patients (54.2%) were men, and 143 patients (45.8%) were women. The median age at diagnosis in the external validation dataset was 72 years (age range, 25--87 years).

### Statistical analysis

Age, race, sex, grade, histology, laterality, AJCC 7th edition TNM stage and status of MPE or MPCE at initial diagnosis were included from the SEER database as the factors in the training cohort. Using this cohort, several multivariate regression models were built, including parametric models and semiparametric models. The performance of the models was compared using the Akaike information criteria (AIC), where the lowest AIC value suggested the best predictive performance. This method has been reported in previous studies on the construction and evaluation of survival models ([@b9-ol-0-0-11112],[@b10-ol-0-0-11112]). The concordance index (C-index) was calculated to evaluate the discriminatory ability of the survival model. A calibration curve was created to show the difference between the predicted and actual survival rate, and data represented the means ± standard error of the mean. A nomogram was created based on the survival prediction model with the lowest AIC. Internal validation was performed using bootstrap resampling, while external validation was performed using an independent cohort. The size of the external validation population was calculated using Vergouwe\'s method ([@b11-ol-0-0-11112]). To determine the discrimination ability of the nomogram, the total scores from the nomogram for each patient in the training and validation datasets were calculated. The patients were then divided into four prognosis groups according to the quartiles of the predicted survival of the training dataset, which were regarded as cutoffs for both the training and validation cohorts. Kaplan-Meier survival curves were constructed for certain TNM categories (M1a and M1b) and all categories in both datasets with the above cutoffs, and the log-rank test was applied for each category. To assess the usefulness of the nomogram and the LENT (pleural fluid lactate dehydrogenase, Eastern Cooperative Oncology Group performance status, neutrophil to lymphocyte ratio and tumor type) scoring system ([@b7-ol-0-0-11112]), receiver operating characteristic (ROC) curves for 3-, 6-, 9- and 12-month survival rates were calculated, and the areas under the curves (AUCs) were also calculated and compared. ROC curves were compared using the DeLong method ([@b12-ol-0-0-11112]). Statistical analyses were formed using R (version 3.5.2; The R Foundation), MedCalc software (version 11.4; MedCalc Software bvba) and SPSS software (version 25.0; IBM Corp.)

Results
=======

### Patient characteristics

A total of 10,268 patients from the SEER database were included in the final population for the survival analysis. Of these, 7,562 patients (73.6%) had adenocarcinomas and 2,706 patients (26.4%) had other histological subtypes, such as large cell carcinomas or squamous cell carcinomas. A total of 5,635 patients (54.9%) exhibited right laterality, 4,075 patients (39.7%) exhibited left laterality and 558 patients (5.4%) had bilateral lesions. This SEER cohort was used as the training dataset. The independent external validation dataset consisted of 312 patients, of whom 266 patients (85.3%) had adenocarcinomas, and 46 patients (14.7%) had other histological types. A total of 175 patients (56.1%) exhibited right primary site laterality, 110 patients (35.2%) exhibited left primary site laterality and 27 patients (8.7%) exhibited bilateral lesion of the primary site. The demographic and clinicopathological characteristics of both cohorts are listed in [Table I](#tI-ol-0-0-11112){ref-type="table"}.

### OS of the training and validation cohorts

The median survival time of the training cohort was 7 months \[95% confidence interval (CI), 6.8--7.2 months\]. The 3-, 6-, 9- and 12-month survival rates of the training cohort were 71.0, 52.4, 38.5 and 28.3%, respectively. The median survival time of the validation cohort was 12.0 months (95% CI, 11.0--13.0 months). The 3-, 6-, 9- and 12-month survival rates of the validation cohort were 85.2, 72.6, 59.4 and 44.5%, respectively (data not shown).

### Development of the survival model

Parametric models and semiparametric models were built using the SEER training cohort. The lognormal model had an AIC of 48483.84, which was the lowest value among the Cox proportional hazard (133573.7), Weibull (49645.39), Gaussian (53229.58), exponential (50999.93), logistic (53440.71) and loglogistic (48902.85) models. The nomogram was developed based on the lognormal model ([Fig. 1](#f1-ol-0-0-11112){ref-type="fig"}). For example, the effusion factor consisted of ipsilateral MPE, contralateral MPE, MPCE, effusion with distant lymph node(s) (DLN), effusion with distant metastases (DM) and effusion with both DM and DLN metastases. Ipsilateral MPE (46.0 points) had the largest point value, which predicted the best survival, whereas effusion with both DM and DLN metastasis (0 point) had the smallest point value, which predicted the worst survival rate. The scores for each variable in the nomogram are listed in [Table II](#tII-ol-0-0-11112){ref-type="table"}.

### Validation and calibration of the survival model

The C-index of the survival model was 0.736 in the training cohort and 0.772 in the validation cohort. Calibration curves were drawn using the internal bootstrap method (A) and with an independent external dataset (B) in [Fig. 2](#f2-ol-0-0-11112){ref-type="fig"}. These curves showed an acceptable fit between the actual and nomogram-predicted probability of OS.

### Risk group stratification

The total points of the present nomogram for each patient in the training and validation cohorts were calculated. Patients in both cohorts were divided into four prognostic groups according to the quartiles of the predicted survival of the training cohort. Kaplan-Meier survival curves were constructed for all patients and for patients with certain M stages (M1a and M1b) in both the training and validation datasets. Significant differences in the 4 prognostic groups were observed for the M1a stage, M1b stage and overall dataset in both cohorts (all P\<0.001; [Fig. 3](#f3-ol-0-0-11112){ref-type="fig"}).

### Comparison of the nomogram with the LENT score in patients with pleural effusion

A total of 303 patients (97.1%) in the validation dataset had pleural effusion. The median score from the LENT system for the validation dataset patients with pleural effusion was 5 (inter-quartile range 3--7). ROC curves were generated to compare the 3-, 6-, 9- and 12-month survival predictions of the LENT scoring system and the present nomogram for the patients with pleural effusion in the validation dataset. The AUC values of the present nomogram were significantly higher compared with the LENT scoring system for predicting 3-, 6- and 12-month survival (all P\<0.05; [Fig. 4](#f4-ol-0-0-11112){ref-type="fig"}). The exception was the prediction of 9-month survival, for which the AUC values for the LENT score and the nomogram were 0.765 (95% CI, 0.714--0.811) and 0.797 (95% CI, 0.748--0.840), respectively (P=0.3513).

Discussion
==========

MPE or MPCE is observed in \>15% of patients at initial diagnosis of NSCLC ([@b3-ol-0-0-11112],[@b13-ol-0-0-11112]). Prediction of survival is important for the stratification and management of patients because it can help physicians select appropriate therapies and identify patients who require palliative care ([@b14-ol-0-0-11112]). The TNM staging system allows for stratification of patients into two (M1a and M1b, AJCC 7th edition) or three (M1a, M1b and M1c, AJCC 8th edition) groups ([@b15-ol-0-0-11112]); however, risk group stratification showed that the present nomogram has an acceptable discrimination ability, even within a specific M stage.

Several predictive models for survival in MPE or MPCE have been published; however, a number of these are based on biomarker concentrations in the serum and/or in the effusion ([@b6-ol-0-0-11112],[@b7-ol-0-0-11112],[@b16-ol-0-0-11112]). In addition to the difficulty in accessing a sufficient effusion sample in patients with a poor physical status or a low effusion volume, the biomarker concentration in a sample can vary due to different measurement techniques ([@b17-ol-0-0-11112]). The application of diuretics can also influence the concentration of biomarkers ([@b18-ol-0-0-11112]), which may limit the usability, accuracy and repeatability of those models.

A recently published study evaluated the performance of the widely used LENT scoring system with an Asian lung adenocarcinoma cohort, and reported that the LENT score underestimated the OS in this distinct group ([@b3-ol-0-0-11112]). This result could be due to the high prevalence of epidermal growth factor receptor (EGFR) mutations in these patients ([@b19-ol-0-0-11112]), and these patients may benefit from tyrosine kinase inhibitor therapy, which leads to prolonged OS ([@b20-ol-0-0-11112]). The nomogram developed in the present study showed that female patients (10.0 points) with adenocarcinoma (22.7 points) and Asian or Pacific Islander ethnicity (40.0 points) had the highest points for each variable, suggesting that patients with these characteristics had longer predicted survival. This may be due to the fact that patients with these characteristics have a high EGFR mutation incidence, and that EGFR mutations predict benefit from treatment ([@b21-ol-0-0-11112],[@b22-ol-0-0-11112]).

Nomograms have been shown to provide more accurate and individualized survival predictions ([@b23-ol-0-0-11112]). In the present study, the nomogram was accurate for the training and validation cohorts. Nomograms are also a useful tool for visualizing prognostic factors ([@b24-ol-0-0-11112]), and the present nomogram revealed different prognoses among each of the factors. Tumor grade is an important independent prognostic marker; however, in the construction of the present prognostic model, it was found that including the tumor grade did not significantly improve the efficiency of the model (data not shown). A possible explanation for this is that the tumor grade may be interrelated with other factors in the present model and that these factors may be highly efficient. Another explanation may be that the present model focused on a specific subgroup, namely patients with stage IV NSCLC. Metastatic tumor cells may be more aggressive due to their heterogeneity, which makes the grade of primary tumor less useful for prognostic predictions ([@b25-ol-0-0-11112]). In the present nomogram, the value of the N component is not arranged regularly from small to large, as the definition of regional lymph nodes in the NSCLC TNM stage system is by lymph node location rather than by the number of positive lymph nodes, which may suggest that patients with MPE and MPCE metastases in specific lymph node locations may have a less favorable prognosis.

The AUCs of the ROC curves for the LENT scoring system in the present validation cohort were quite similar to those in the report of the LENT study ([@b7-ol-0-0-11112]). The AUCs were reported to be 0.7571 for 3 months and 0.8094 for 6 months in the LENT scoring system for the UK cohort 2 ([@b7-ol-0-0-11112]), and in the present study the AUCs were 0.812 for 3 months and 0.794 for 6 months. The ROC curves showed that the present nomogram, based on demographic and clinicopathological characteristics, may provide a similar 9-month survival prediction as that generated by the LENT scoring system and better predictions for 3-, 6- and 12-month survival. Therefore, the present nomogram may be an additional option for physicians to predict survival of patients with NSCLC with MPE or MPCE at the initial diagnosis.

The median survival of the validation cohort was longer than that of the training cohort and this may be due to differences in the races of the patients included in each cohort. However, the present nomogram still provided a good prediction of outcomes for the patients in the validation cohort, as the point values were 13.8 for white patients and 40.0 for Asian patients in the race factor of the predictive model. This observation suggested that the present nomogram remained robust in a homogeneous Asian population and thus indicated that the nomogram may be preferably used for Asian patients. Nevertheless, further studies that validate this nomogram in a cohort with races are still required.

As the SEER database contains retrospective data and uses a collaborative stage data collection system that records only coding data to protect the identities of cancer patients ([@b26-ol-0-0-11112]), it is difficult to precisely convert the patient data recorded with the AJCC 7th edition of TNM staging to the AJCC 8th edition. The nomogram of the present study is depicted with the AJCC 7th edition. However, the difference between the 7th and 8th editions is that the specific Tumor component is small and these differences are well known to specialists; however, no change was made to the Node component. Therefore, any inconsistencies caused by the differences in editions of the staging system when using the present nomogram should be minimal.

The present study had several limitations. Firstly, some of the clinicopathological variables and molecular markers, such as physical status ([@b27-ol-0-0-11112],[@b28-ol-0-0-11112]), EGFR mutation and PD-L1 status, which may influence the survival of patients with lung cancer ([@b22-ol-0-0-11112],[@b29-ol-0-0-11112]), are not included in the SEER database; however, these biomarkers are more predictive than prognostic, which may limit their use in a prognosis prediction model ([@b30-ol-0-0-11112]). Secondly, the time of disease progression was not available in the SEER database, thus it was not possible to construct predictive models of progression-free survival. Additionally, the nomogram developed in the present study performed better for cases near the median; whereas for discrete cases the predictive performance was poor, which is a common limitation of predictive models ([@b31-ol-0-0-11112]). MPCE was included in the present study as the SEER database used a 'CS Mets at DX' item to describe MPE or MPCE. Each patient was categorized into a specific group, such as 'DLN + MPE or MPCE', 'DM + MPE or MPCE', MPE, and 'MPE + MPCE'. Thus, it was difficult to determine whether a patient in the 'DLN + MPE or MPCE' group had MPE or MPCE, and excluding this group may have led to a bias in the predicted model. Finally, although the present nomogram was built based on a large population and was calibrated by both internal bootstrap resampling and an external cohort, the external cohort was collected from one district, which may lead to potential bias in validation and calibration, including the limited diversity of patient characteristics. A large external validation cohort is required to confirm the nomogram.

In conclusion, nomograms may provide a precise and easily understandable illustration of survival for healthcare providers of patients with lung cancer with MPE or MPCE at the initial diagnosis. In the present study, a nomogram was constructed for predicting the survival of patients with NSCLC with MPE or MPCE at initial diagnosis based on the SEER database. The nomogram developed in the present study may improve prognostic prediction and disease management for patients with lung cancer.
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![Prognostic nomogram for patients with NSCLC with MPE or MPCE. The points for each variable was added up to obtain the total points and the final scores were used to estimate 3-, 6-, 9- and 12-month survival. NSCLC, non-small cell lung cancer; Overlapping, overlapping lesion of lung; Main, main bronchus; NOS, not otherwise specified lesion of lung; Upper, upper lobe of lung; Middle, middle lobe of lung; Lower, lower lobe of lung; MPE, malignant pleural effusion; MPCE, malignant pericardial effusion; DLN, distant lymph node(s); DM, distant metastasis.](ol-19-01-0449-g00){#f1-ol-0-0-11112}

![Calibration plots of the training and validation cohorts. The x-axis shows the proportion of actual OS, while the y-axis shows the probability. The gray reference line indicates that the nomogram predicted OS is equal to the actual OS. Data represented the means ± standard error of the mean. (A) Internal bootstrap method; (B) External validation cohort. OS, overall survival.](ol-19-01-0449-g01){#f2-ol-0-0-11112}

![Risk group stratification of overall survival in the training and validation cohorts. Patients in each category were divided into four prognostic groups according to the quartiles of predicted survival. A Kaplan-Meier plot of probability of survival is presented for each quartile group. Min, Minimum; CI, confidence interval; NA, Not Applicable; Max, Maximum; M1a, according to the AJCC 7th edition of TNM staging; M1b, according to the AJCC 7th edition of TNM staging.](ol-19-01-0449-g02){#f3-ol-0-0-11112}

![ROC curves of the present nomogram and the LENT scoring system in the validation cohort. ROC, receiver operating characteristic; AUC, area under the curve; LENT, the LENT (pleural fluid lactate dehydrogenase, Eastern Cooperative Oncology Group performance status, neutrophil to lymphocyte ratio and tumor type) prognostic score.](ol-19-01-0449-g03){#f4-ol-0-0-11112}

###### 

Demographic and clinicopathological characteristics of the training cohort and validation cohort.

  A, Training cohort, n=10268                                            
  ----------------------------------------- ---------------------------- ----------------------------
  Sex                                                                    
    Male                                    5,827 (56.7)                 6 (5.76--6.24)
    Female                                  4,441 (43.3)                 8 (7.67--8.33)
  Age at diagnosis, years                                                
    ≤70                                     5,171 (50.4)                 9 (8.68--9.32)
    \>70                                    5,097 (49.6)                 5 (4.79--5.21)
  Race                                                                   
    American Indian/Alaska Native           43 (0.4)                     5 (1.85--8.15)
    Asian or Pacific Islander               881 (8.6)                    12 (11.12--12.88)
    Black                                   1,472 (14.3)                 7 (6.42--7.58)
    White                                   7,872 (76.7)                 7 (6.80--7.20)
  Primary site                                                           
    Main bronchus                           635 (6.2)                    5 (4.38--5.62)
    Upper lobe                              4,228 (41.2)                 7 (6.69--7.31)
    Middle lobe                             381 (3.7)                    8 (7.04--8.96)
    Lower lobe                              2,500 (24.3)                 8 (7.60--8.40)
    Overlapping lesion                      156 (1.5)                    5 (3.72--6.28)
    Lung, NOS                               2,368 (23.1)                 6 (5.62--6.38)
  Histology                                                              
    Large cell carcinoma                    246 (2.4)                    4 (3.21--4.78)
    Adenocarcinoma                          7,562 (73.6)                 7 (6.77--7.23)
    Squamous cell carcinoma                 2,460 (24)                   6 (5.65--6.35)
  Grade                                                                  
    I                                       219 (2.1)                    10 (8.22--11.79)
    II                                      1,221 (11.9)                 8 (7.35--8.66)
    III                                     2,211 (21.5)                 7 (6.59--7.41)
    IV                                      95 (0.9)                     4 (2.57--5.43)
    Unknown                                 6,522 (63.5)                 7 (6.76--7.24)
  Laterality                                                             
    Right                                   5,635 (54.9)                 7 (6.74--7.26)
    Left                                    4,075 (39.7)                 7 (6.69--7.31)
    Bilateral                               558 (5.4)                    6 (5.26--6.74)
  T stage                                                                
    T0                                      111 (1.1)                    8 (6.21--9.80)
    T1                                      495 (4.8)                    10 (8.91--11.09)
    T2                                      2,522 (24.6)                 8 (7.56--8.44)
    T3                                      2,430 (23.7)                 7 (6.56--7.44)
    T4                                      3,083 (30)                   6 (5.69--6.32)
    Tx                                      1,627 (15.8)                 6 (5.53--6.48)
  N stage                                                                
    N0                                      2,174 (21.2)                 9 (8.52--9.48)
    N1                                      550 (5.4)                    8 (7.03--8.97)
    N2                                      4,571 (44.5)                 6 (5.75--6.25)
    N3                                      2,167 (21.1)                 7 (6.60--7.40)
    Nx                                      806 (7.8)                    5 (4.44--5.56)
  M stage                                                                
    M1a                                     4,611 (44.9)                 10 (9.65--10.35)
    M1b                                     5,657 (55.1)                 5 (4.79--5.21)
  Effusions at diagnosis                                                 
    MPE, Ipsilateral                        3,028 (29.5)                 10 (9.57--10.43)
    MPE, Contralateral                      145 (1.4)                    10 (8.31--11.69)
    MPE, Bilateral                          524 (5.1)                      8 (7.12--8.88)
    MPE, unknown                            342 (3.3)                      8 (7.05--8.95)
    MPCE                                    366 (3.6)                    10 (8.98--11.02)
    MPCE + MPE                              206 (2.0)                      8 (6.75--9.25)
    DLN + MPE or MPCE                       336 (3.3)                      9 (8.00--10.00)
    DM + MPE or MPCE                        4,329 (42.1)                   5 (4.78--5.22)
    DM + DLN + MPE or MPCE                  992 (9.7)                      5 (4.54--5.46)
                                                                         
  **B, Validation set, n=312**                                           
                                                                         
  **Clinicopathological characteristics**   **Number of patients (%)**   **Median OS, months (CI)**
                                                                         
  Sex                                                                    
    Male                                    169 (54.2)                   11 (9.54--12.46)
    Female                                  143 (45.8)                   12 (10.27--13.73)
  Age at diagnosis, years                                                
    ≤70                                     140 (44.9)                   14 (12.23--15.77)
    \>70                                    172 (55.1)                   9 (7.37--10.64)
  Race                                                                   
    American Indian/Alaska Native           NA                           NA
    Asian or Pacific Islander               312 (100)                    12 (11.04--12.96)
    Black                                   NA                           NA
    White                                   NA                           NA
  Primary site                                                           
    Main bronchus                           13 (4.2)                     9 (2.64--15.36)
    Upper lobe                              119 (38.1)                   13 (11.86--14.14)
    Middle lobe                             11 (3.5)                     12 (4.72--19.28)
    Lower lobe                              69 (22.1)                    12 (9.73--14.27)
    Overlapping lesion                      7 (2.2)                      4 (1.43--6.57)
    Lung, NOS                               93 (29.8)                    9 (6.38--11.62)
  Histology                                                              
    Large cell carcinoma                    5 (1.6)                      2 (0.00--4.15)
    Adenocarcinoma                          266 (85.3)                   12 (10.83--13.17)
    Squamous cell carcinoma                 41 (13.1)                    9 (6.44--11.56)
  Grade                                                                  
    I                                       219 (70.2)                   11 (9.56--12.45)
    II                                      4 (1.3)                      21 (NA)
    III                                     41 (13.1)                    13 (11.93--14.07)
    IV                                      48 (15.4)                    13 (9.53--16.47)
    Unknown                                 NA                           NA
  Laterality                                                             
    Right                                   175 (56.1)                   12 (10.95--13.05)
    Left                                    110 (35.2)                   12 (9.55--14.45)
    Bilateral                               27 (8.7)                     11 (5.33--16.68)
  T stage                                                                
    T0                                      5 (1.6)                      NA
    T1                                      10 (3.2)                     25 (0.84--49.17)
    T2                                      67 (21.5)                    14 (10.99--17.01)
    T3                                      67 (21.5)                    13 (10.16--15.84)
    T4                                      93 (29.8)                    11 (8.03--13.97)
    Tx                                      70 (22.4)                    9 (6.77--11.23)
  N stage                                                                
    N0                                      52 (16.7)                    12 (9.53--14.47)
    N1                                      15 (4.8)                     14 (10.77--17.23)
    N2                                      138 (44.2)                   11 (9.68--12.32)
    N3                                      64 (20.5)                    12 (10.5--13.50)
    Nx                                      43 (13.8)                    9 (6.78--11.22)
  M stage                                                                
    M1a                                     142 (45.5)                   13 (11.56--14.44)
    M1b                                     170 (54.5)                   10 (8.08--11.92)
  Effusions at diagnosis                                                 
    MPE, Ipsilateral                        100 (32.0)                   14 (11.93--16.07)
    MPE, Contralateral                      2 (0.6)                      12 (NA)
    MPE, Bilateral                          8 (2.6)                      8 (2.46--13.54)
    MPE, unknown                            15 (4.8)                     9 (7.28--10.73)
    MPCE                                    9 (2.9)                      14 (12.61--15.39)
    MPCE + MPE                              8 (2.6)                      9 (3.39--14.62)
    DLN + MPE or MPCE                       10 (3.2)                     12 (9.22--14.79)
    DM + MPE or MPCE                        118 (37.8)                   10 (7.96--12.05)
    DM + DLN + MPE or MPCE                  42 (13.5)                    8 (5.67--10.33)

Grading with the ICD-O-3 (International Classification of Diseases for Oncology) histologic grading system; NOS, not otherwise specified; T, tumor; N, node; M, metastasis; MPE, malignant pleural effusion; MPCE, malignant pericardial effusion; DLN, distant lymph nodes; DM, distant metastasis; NA, not available.

###### 

Points assignment for each variable.

  Variables                         Points
  --------------------------------- --------
  Sex                               
    Male                            0
    Female                          10.0
  Age at diagnosis, years           
    ≤30                             100.0
    \>30, ≤40                       90.0
    \>40, ≤50                       63.3
    \>50, ≤60                       46.4
    \>60, ≤70                       39.0
    \>70, ≤80                       21.4
    \>80                            0
  Primary site                      
    Main bronchus                   9.5
    Upper lobe                      22.9
    Middle lobe                     23.7
    Lower lobe                      27.1
    Overlapping lesion              0
    Lung, NOS                       13.5
  Histology                         
    Large cell carcinoma            0
    Adenocarcinoma                  22.7
    Squamous cell carcinoma         12.6
  T stage                           
    T0                              12.8
    T1                              21.2
    T2                              14.3
    T3                              7.6
    T4                              7.4
    Tx                              0
  N stage                           
    N0                              19.6
    N1                              13.8
    N2                              6.4
    N3                              10.6
    Nx                              0
  Effusions at diagnosis            
    MPE, Ipsilateral                46.0
    MPE, Contralateral              45.2
    MPE, Bilateral                  36.9
    MPE, unknown                    43.1
    MPCE                            37.9
    MPCE + MPE                      24.4
    DLN + MPE or MPCE               36.8
    DM + MPE or MPCE                4.2
    DM + DLN + MPE or MPCE          0
  Race                              
    American Indian/Alaska Native   0
    Asian or Pacific Islander       40.0
    Black                           11.7
    White                           13.8

NOS, not otherwise specified; T, tumor; N, node; M, metastasis; MPE, malignant pleural effusion; MPCE, malignant pericardial effusion; DLN, distant lymph node(s); DM, distant metastasis.
